Ikaros gene expression and leukemia.

Abstract

The Ikaros (Ik) protein, or LyF1, was initially described as a protein binding to regulatory sequences of a number of genes expressed in murine lymphoid cells. Ikaros is a critical regulator of normal hematopoietic stem cell differentiation, as evidenced by dramatic defects in the lymphoid compartments, in homozygous animals with gene inactivation. Because differential splicing produces multiple isoforms with potentially different functions, Ikaros provides a unique model to study how post-transcriptional mechanisms may be involved in neoplastic processes. Indeed, several groups including ours have underlined evidences that expression of different Ikaros isoforms vary among different types of leukemias. The predominance of short isoforms in certain subsets is intriguing. Here, additional observations reinforced the hypothesis that Ikaros expression may be deregulated in human leukemias. Whether this is a cause or a consequence of the leukemic process remains speculative. Other human diseases however, provide examples of abnormal post-transcriptional regulations that have been further characterized.

• Authors: Cécile Tonnelle, Boris Calmels, Christine Maroc, Jean Gabert, Christian Chabannon
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 43 Issue 1 Pg. 29-35 (Jan 2002) ISSN: 1042-8194 [Print] United States
• PMID: 11908734 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• DNA-Binding Proteins
• IKZF1 protein, human
• Protein Isoforms
• Transcription Factors
• Ikaros Transcription Factor

Topics

• Alternative Splicing
• Animals
• DNA-Binding Proteins
• Gene Expression Regulation, Neoplastic
• Humans
• Ikaros Transcription Factor
• Leukemia (etiology, genetics, pathology)
• Mutation
• Protein Isoforms (genetics, metabolism)
• Transcription Factors (genetics, metabolism)